Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.77 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.77 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.77 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.77 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.77 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.77 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.77 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.77 |
| ▸ | DRD3 | P35462 | 5/20 | 0.77 |
| ▸ | DRD2 | P14416 | 5/20 | 0.77 |
| ▸ | HRH2 | P25021 | 2/20 | 0.77 |
| ▸ | DRD4 | P21917 | 2/20 | 0.77 |
| ▸ | HTR2A | P28223 | 1/20 | 0.77 |
| ▸ | HTR7 | P34969 | 1/20 | 0.77 |
| ▸ | HRH1 | P35367 | 1/20 | 0.77 |
| ▸ | HTR2B | P41595 | 1/20 | 0.77 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.77 |
| ▸ | SCN3A | Q9NY46 | 5/20 | 0.60 |
| ▸ | SCN4A | P35499 | 4/20 | 0.60 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7859028 | 0.98 | DRD3 (0.79) | DRD3DRD2HRH2ADRA2ADRD4 | |
| SCHEMBL8244275 | 0.98 | DRD3 (0.79) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Hydrochloric Acid SCHEMBL7313270 | 0.97 | ADRA2A (0.80) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Pramipexole SCHEMBL3947668 | 0.89 | DRD3 (0.97) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Pramipexole SCHEMBL4144177 | 0.89 | DRD3 (0.97) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Pramipexole SCHEMBL1234941 | 0.89 | DRD3 (0.97) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Pramipexole SCHEMBL1193565 | 0.89 | DRD3 (0.97) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Pramipexole SCHEMBL35376 | 0.87 | DRD3 (1.00) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Dexpramipexole SCHEMBL74780 | 0.87 | DRD3 (1.00) | DRD3DRD2HRH2ADRA2ADRD4 | |
| Pramipexole SCHEMBL195775 | 0.87 | DRD3 (1.00) | DRD3DRD2HRH2ADRA2ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220060-B1 | TETRAHYDROBENZOTHIAZOLE DERIVATIVES | MOTAC NEUROSCIENCE LTD (GB) | 2016-09-14 | — | — | EP | disclosed |
| US-8389555-B2 | Medicaments | MOTAC NEUROSCIENCE LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-20110046153-A1 | Medicaments | MOTAC NEUROSCIENCE LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| EP-2220060-A1 | MEDICAMENTS | Motac Neuroscience Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009056811-A2 | MEDICAMENTS | MOTAC NEUROSCIENCE LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009056805-A1 | MEDICAMENTS | MOTAC NEUROSCIENCE LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046153-A1 | Medicaments | MTNR1A, SIGMAR1, OPRK1 | ADRA2A 18/4885ADRB2 11/4885HTR1A 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.